Business Wire

  1. U.S. FDA Grants Orphan Drug Designation To Leukogene Therapeutics' M2T-CD33 (LTI-214) For The Treatment Of Acute Myeloid Leukemia 11/5/2025

    Leukogene Therapeutics Inc. (LTI), a biopharmaceutical company developing next-generation immunotherapies for hematologic and other malignancies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the Company’s lead product candidate, M2T-CD33 (LTI-214), for the treatment of Acute Myeloid Leukemia (AML).

  2. Manifold Bio Announces Strategic Collaboration With Roche To Develop Multiple Next-Generation Brain Shuttles For Neurological Diseases 11/3/2025

    Manifold Bio, a platform therapeutics company pioneering AI-guided drug discovery coupled with direct-to-vivo measurement, today announced a strategic research collaboration and license agreement with Roche.

  3. Debiopharm Forges AI-powered Alliance With NetTargets To Pioneer Dual-Payload ADCs Against Drug-Resistant Cancers 10/30/2025

    Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based, biopharmaceutical company dedicated to developing innovative therapies that respond to high unmet medical needs, today announced a strategic research collaboration with NetTargets (www.net-targets.com), a South Korean biotech company specializing in AI-enhanced systems biology for drug discovery, to rationally design and advance the discovery of novel, synergistic drug combinations for Debiopharm’s next-generation Antibody-Drug Conjugates (ADCs).

  4. Foundation Medicine And Manifold Partner To Accelerate Drug Discovery And Development By Bringing AI-Enabled Analytics To FoundationInsights 10/30/2025

    Foundation Medicine, Inc., a precision medicine company transforming lives in cancer care and beyond, today announced a partnership with Manifold, the leading artificial intelligence (AI) data platform for life sciences, to bring enhanced AI capabilities to FoundationInsights, a cloud-based data analytics and visualization platform that derives insights from Foundation Medicine’s proprietary multimodal datasets.

  5. Lantern Pharma To Present AI-Driven Cancer Drug Development & Research Platforms At Inaugural AI For Biology And Medicine Symposium At UNT 10/30/2025

    Lantern Pharma Inc. — Lantern today announced it will present two commercially deployed AI research platforms at the inaugural AI for Biology and Medicine (AI4BM) symposium at the University of North Texas.

  6. Enigma Biomedical USA Announces FDA Acceptance Of New Drug Application For Florquinitau F-18 (MK-6240), A Tau PET Alzheimer's Disease Radiodiagnostic 10/28/2025

    Enigma Biomedical USA (EB USA) today announced that the Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for MK-6240 (florquinitau F-18), their Tau Positron Emission Tomography (PET) Alzheimer’s disease radiodiaganostic.

  7. Genesis Molecular AI Unveils Pearl, A Field-Leading Foundation Model That Achieves Unprecedented Performance In Drug-Protein Structure Prediction 10/28/2025

    Genesis Molecular AI, the company pioneering the world’s leading molecular AI models for drug design and development, today announced Pearl, a generative foundation model for biomolecular structure prediction trained with novel architecture, training methodology, and large-scale synthetic data.

  8. Merck Partners With Promega To Advance 3-D Cell Drug Discovery Technologies 10/28/2025

    Merck, a leading science and technology company, has entered into a partnership with Promega Corporation, a global life science solutions and service leader based in Madison, Wisconsin in the US, to co-develop novel technologies that advance drug screening and discovery.

  9. Alloy Therapeutics Announces Acquisition Of Spannerwerks, A Leading Provider Of Drug Development Consulting Services 10/23/2025

    Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug discovery technologies, today announced the acquisition of Spannerwerks, LLC, a Seattle-based professional services firm that guides biopharmaceutical companies on the development and launch of new products.

  10. Invenra Inc. And Xcellon Biologics Announce Collaboration To Advance Bispecific And Trispecific Antibody-Drug Conjugate (ADC) Development 10/22/2025

    Invenra Inc., a U.S.-based biotechnology company pioneering multispecific antibody platform technologies, and Xcellon Biologics, a wholly owned subsidiary of Linden Lake Labs and a U.S.-based contract development and manufacturing organization (CDMO) specializing in antibody–drug conjugates (ADCs) and complex biologics, today announced a strategic collaboration to advance the development of multispecific ADCs.